Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 4:55 pm Purchase |
2024-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
ARCH Venture Fund IX, L.P. | 36,597,716 13.100% |
120,000 (+0.33%) |
Filing History |
| 2025-02-14 2:20 pm Purchase |
2024-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
Foresite Capital Fund IV, L.P. | 19,478,893 6.700% |
5,795,035 (+42.35%) |
Filing History |
| 2025-02-05 1:23 pm Sale |
2024-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
BlackRock Inc. BLK |
13,265,869 4.500% |
-1,036,351 (-7.25%) |
Filing History |
| 2024-11-12 4:04 pm Unchanged |
2024-09-30 | 13G | Lyell Immunopharma, Inc. LYEL |
The Vanguard Group | 10,071,482 3.930% |
0 (Unchanged) |
Filing History |
| 2024-11-04 1:30 pm Sale |
2024-09-30 | 13G | Lyell Immunopharma, Inc. LYEL |
The Vanguard Group | 10,071,482 3.930% |
-3,532,545 (-25.97%) |
Filing History |
| 2024-10-31 6:00 pm Purchase |
2024-10-25 | 13G | Lyell Immunopharma, Inc. LYEL |
Foresite Capital Fund IV, L.P. | 13,683,858 5.300% |
3,683,858 (+36.84%) |
Filing History |
| 2024-02-14 3:18 pm Purchase |
2023-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
ARCH Venture Fund IX, L.P. | 36,477,716 14.500% |
65,000 (+0.18%) |
Filing History |
| 2024-02-13 5:08 pm Purchase |
2023-12-29 | 13G | Lyell Immunopharma, Inc. LYEL |
The Vanguard Group | 13,604,027 5.400% |
1,012,797 (+8.04%) |
Filing History |
| 2024-01-29 5:25 pm Purchase |
2023-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
BlackRock Inc. BLK |
14,302,220 5.700% |
14,302,220 (New Position) |
Filing History |
| 2023-02-13 5:02 pm Sale |
2022-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
Foresite Capital Fund IV, L.P. | 10,000,000 4.000% |
-3,282,181 (-24.71%) |
Filing History |
| 2023-02-09 11:25 am Purchase |
2022-12-30 | 13G | Lyell Immunopharma, Inc. LYEL |
The Vanguard Group | 12,591,230 5.050% |
12,591,230 (New Position) |
Filing History |
| 2022-02-14 4:17 pm Purchase |
2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
MWG Management Ltd. | 20,162,332 8.380% |
20,162,332 (New Position) |
Filing History |
| 2022-02-14 4:10 pm Purchase |
2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
NEWTON (PTC) Ltd | 15,093,969 6.280% |
15,093,969 (New Position) |
Filing History |
| 2022-02-14 12:04 pm Purchase |
2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
ARCH Venture Fund IX, L.P. | 36,412,716 15.100% |
36,412,716 (New Position) |
Filing History |
| 2022-02-11 3:10 pm Purchase |
2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
Foresite Capital Fund IV, L.P. | 13,282,181 5.500% |
13,282,181 (New Position) |
Filing History |
| 2022-02-10 4:51 pm Purchase |
2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
GSK PLC | 30,253,189 12.600% |
30,253,189 (New Position) |
Filing History |